6YG.F IMMUNOCORE HLDGS ADS/1

Healthcare Biotechnology Frankfurt Exchange
28.20 EUR
Close of Nov 11, 2026
23.20 35.60
Market cap
EUR 1.45B
P/E
-
P/B
3.97x
ROE
-0.7%
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.

Is 6YG.F undervalued?

Graham number

The Graham number of IMMUNOCORE HLDGS ADS/1 cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

IMMUNOCORE HLDGS ADS/1 fundamental analysis

No fundamental analysis for IMMUNOCORE HLDGS ADS/1 yet.

IMMUNOCORE HLDGS ADS/1 stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About IMMUNOCORE HLDGS ADS/1

Immunocore Holdings plc, together with its subsidiaries, engages in the development and commercialization of immunomodulating medicines for patients with cancer, infectious diseases, and autoimmune disease in the United States, Europe, and internationally. The company offers KIMMTRAK for the treatment of unresectable or metastatic uveal melanoma. It also develops oncology programs, including tebentafusp which is in Phase 3 clinical trial for the treatment of advanced cutaneo…

Full company profile